A leap towards enforcing medicines prescribing by generic names in low- and middle-income countries (LMICs): pitfalls, limitations, and recommendations for local drug regulatory agencies
The Drug Regulatory Authority of Pakistan (DRAP) in response to the public outcry on increasing medicines prices in the country issued notifications to direct healthcare professionals to prescribe medicines with their generic names. Like DRAP, many regulators in the low- and middle-income countries...
Main Authors: | Hamid A. Merchant, Zaheer-Ud-Din Babar, Izhar M. Hussain |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2022-12-01
|
Series: | Journal of Pharmaceutical Policy and Practice |
Subjects: | |
Online Access: | http://dx.doi.org/10.1186/s40545-022-00501-4 |
Similar Items
-
Update on the advances and challenges in bioequivalence testing methods for complex topical generic products
by: Nedaa Alomari, et al.
Published: (2024-02-01) -
Regulatory requirements for the registration of generic medicines and format of drug dossiers: procedures in Sri Lanka in comparison with selected regulatory authorities
by: D. Thambavita, et al.
Published: (2018-12-01) -
Open questions on bioequivalence: the case of cholecalciferol
by: Antonio Marzo, et al.
Published: (2013-09-01) -
Application in silico Modeling Simulation in Bioequivalence Studies: A Review
by: Sekar Ayu Pawestri
Published: (2023-03-01) -
Generic medicine and prescribing: A quick assessment
by: Mainul Haque
Published: (2017-01-01)